Lung Cancer Trials Ask AI to find trials
CompletedNot applicableNCT03824366
Official study title

Same-session MR-only Simulation and Treatment With MRI-guided Adaptive Palliative RadioTherapy

Study summary

This proposed study is unique in that patients will not undergo computed tomography (CT) simulation at any point during their treatment course and will instead have same-session magnetic resonance (MR)-only simulation and treatment planning, on-table, using the adaptive radiotherapy (ART) workflow. In this manner, patients requiring urgent treatment could initiate treatment as early as the day of initial radiation oncology consultation.

Ask AI to explain this study
Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedVolumetric MR imaging and Radiation therapy

The study team can explain what participation involves.

Who it may be forMalignancy · Metastasis

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Jan 10, 2025 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Not applicable

Interventional

Where is it offered?1 U.S. location

Locations may change over time.

Who runs it?Washington University School of Medicine

Study sponsor

01
Study overview

What this study is about

Purpose
Treatment
Study type
Interventional
Phase
Not applicable
Sponsor
Washington University School of Medicine
Interventions being studied
Device: Volumetric MR imaging; Radiation: Radiation therapy
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Treatment approach
Radiation therapy→Supportive or behavioral care→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Diagnosis of malignancy (biopsy proven or high clinical suspicion with urgent/emergent clinical indications for palliative RT)
  • Requires delivery of palliative radiation therapy for the treatment of painful metastasis, hemoptysis, gastrointestinal bleeding, pelvic bleeding, or superior vena cava syndrome/bulky mediastinal disease.
  • At least 18 years of age.
  • Able to understand and willing to sign an IRB-approved written informed consent document.
Reasons someone may not be able to joinExclusion criteria
  • Pregnant. Patients of childbearing potential must have a negative pregnancy test within 14 days of study entry.
  • Medical contraindication to undergoing MR imaging.

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Washington University School of MedicineSt Louis, Missouri

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jan 10, 2025. Always confirm current availability with the study team.

View original record ↗